scholarly journals Exacerbation of C1q dysregulation, synaptic loss and memory deficits in tau pathology linked to neuronal adenosine A2A receptor

Brain ◽  
2019 ◽  
Vol 142 (11) ◽  
pp. 3636-3654 ◽  
Author(s):  
Kevin Carvalho ◽  
Emilie Faivre ◽  
Marie J Pietrowski ◽  
Xavier Marques ◽  
Victoria Gomez-Murcia ◽  
...  

See Cunha (doi:10.1093/brain/awz335) for a scientific commentary on this article. Carvalho et al. provide clues to the onset of immune dysregulation underlying early synaptic loss in Alzheimer’s disease and tauopathies, by linking overactivation of adenosine A2A receptors in tau pathology to a particular microglial signature (upregulation of C1q and TREM2) allied to the loss of glutamatergic synapses and cognitive deficits.

Brain ◽  
2019 ◽  
Vol 142 (11) ◽  
pp. 3323-3324 ◽  
Author(s):  
Rodrigo A Cunha

This scientific commentary refers to ‘Exacerbation of C1q dysregulation, synaptic loss and memory deficits in tau pathology linked to neuronal adenosine A2A receptors’, by Carvalho et al. (doi:10.1093/brain/awz288).


Glia ◽  
2018 ◽  
Vol 67 (1) ◽  
pp. 182-192 ◽  
Author(s):  
Joana Mendes Duarte ◽  
Rita Gaspar ◽  
Liliana Caetano ◽  
Patrícia Patrício ◽  
Carina Soares-Cunha ◽  
...  

2011 ◽  
Vol 5 ◽  
Author(s):  
Sergi Ferré ◽  
César Quiroz ◽  
Marco Orru ◽  
Xavier Guitart ◽  
Gemma Navarro ◽  
...  

Biomedicines ◽  
2021 ◽  
Vol 9 (8) ◽  
pp. 1027
Author(s):  
Akihisa Mori ◽  
Brittany Cross ◽  
Shinichi Uchida ◽  
Jill Kerrick Walker ◽  
Robert Ristuccia

Adenosine is extensively distributed in the central and peripheral nervous systems, where it plays a key role as a neuromodulator. It has long been implicated in the pathogenesis of progressive neurogenerative disorders such as Parkinson’s disease, and there is now growing interest in its role in amyotrophic lateral sclerosis (ALS). The motor neurons affected in ALS are responsive to adenosine receptor function, and there is accumulating evidence for beneficial effects of adenosine A2A receptor antagonism. In this article, we focus on recent evidence from ALS clinical pathology and animal models that support dynamism of the adenosinergic system (including changes in adenosine levels and receptor changes) in ALS. We review the possible mechanisms of chronic neurodegeneration via the adenosinergic system, potential biomarkers and the acute symptomatic pharmacology, including respiratory motor neuron control, of A2A receptor antagonism to explore the potential of the A2A receptor as target for ALS therapy.


2007 ◽  
Vol 87 (1) ◽  
pp. 42-56 ◽  
Author(s):  
Lydia Giménez-Llort ◽  
Serge N. Schiffmann ◽  
Tanja Shmidt ◽  
Laia Canela ◽  
Lluïsa Camón ◽  
...  

2004 ◽  
Vol 20 (8) ◽  
pp. 2203-2213 ◽  
Author(s):  
Guadalupe Soria ◽  
Anna Castane ◽  
Fernando Berrendero ◽  
Catherine Ledent ◽  
Marc Parmentier ◽  
...  

2004 ◽  
Vol 30 (5) ◽  
pp. 891-900 ◽  
Author(s):  
Elena Bastia ◽  
Yue-Hang Xu ◽  
Angela C Scibelli ◽  
Yuan-Ji Day ◽  
Joel Linden ◽  
...  

1998 ◽  
Vol 9 (Supplement) ◽  
pp. S93
Author(s):  
J. Wardasa ◽  
A. Pinna ◽  
A. Cozzolino ◽  
M. Morellib

Sign in / Sign up

Export Citation Format

Share Document